Advances in oncology. Panitumumab and combination chemotherapy in first- and second-line therapy for colorectal cancer.
Chan
Emily
E
Vanderbilt-Ingram Cancer Center, Nashville, TN 37232, USA.
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D000077544:Panitumumab; D016032:Randomized Controlled Trials as Topic
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000077544:Panitumumab